{"id":"botulinum-toxin-type-a-day-0","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Headache"},{"rate":"5–10","effect":"Injection site pain or bruising"},{"rate":"1–5","effect":"Eyelid ptosis"},{"rate":"1–3","effect":"Facial weakness or asymmetry"},{"rate":"1–3","effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.","oneSentence":"Botulinum toxin type-A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:23.978Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Facial wrinkles and expression lines (aesthetic use)"},{"name":"Blepharospasm"},{"name":"Cervical dystonia"},{"name":"Chronic migraine"},{"name":"Hyperhidrosis"}]},"trialDetails":[{"nctId":"NCT06047457","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-09-29","conditions":"Episodic Migraine","enrollment":751},{"nctId":"NCT06047444","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-10-12","conditions":"Chronic Migraine","enrollment":759},{"nctId":"NCT07270042","phase":"NA","title":"Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection","status":"NOT_YET_RECRUITING","sponsor":"Tishreen University","startDate":"2025-12-01","conditions":"Hyperactive Masseter Muscle","enrollment":20},{"nctId":"NCT07025044","phase":"","title":"Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections","status":"RECRUITING","sponsor":"Alexis Dieter","startDate":"2025-09-03","conditions":"Overactive Bladder (OAB), Urge Incontinence","enrollment":40},{"nctId":"NCT06840158","phase":"PHASE3","title":"Double-blind Comparative Randomized Multicenter","status":"COMPLETED","sponsor":"Innopharm LLC","startDate":"2021-10-15","conditions":"Cerebral Palsy (CP)","enrollment":80},{"nctId":"NCT05284019","phase":"PHASE4","title":"Real World Effectiveness of Eptinezumab in Participants With Migraine","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2022-03-04","conditions":"Migraine","enrollment":32},{"nctId":"NCT06385171","phase":"","title":"Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation","status":"RECRUITING","sponsor":"Global Aesthetics LLC","startDate":"2024-05-22","conditions":"Wrinkle","enrollment":500},{"nctId":"NCT00636519","phase":"PHASE1","title":"Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2008-02","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT05801146","phase":"PHASE3","title":"Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines","status":"UNKNOWN","sponsor":"Hugel","startDate":"2024-01-04","conditions":"Glabellar Lines","enrollment":272},{"nctId":"NCT03712449","phase":"PHASE4","title":"A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-01-22","conditions":"Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality","enrollment":59},{"nctId":"NCT05590520","phase":"NA","title":"Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure","status":"UNKNOWN","sponsor":"Pak Emirates Military Hospital","startDate":"2022-11-01","conditions":"Fissure in Ano","enrollment":90},{"nctId":"NCT04944953","phase":"PHASE1","title":"To Compare the Safety and Efficacy of \"HG-102\" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.","status":"COMPLETED","sponsor":"Hugel","startDate":"2021-06-11","conditions":"Glabellar Lines","enrollment":38},{"nctId":"NCT01791920","phase":"PHASE3","title":"To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"Hugel","startDate":"2011-08","conditions":"Skin Aging","enrollment":262},{"nctId":"NCT04830345","phase":"PHASE3","title":"Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2020-06-29","conditions":"Glabellar Frown Lines","enrollment":290},{"nctId":"NCT00711087","phase":"PHASE2","title":"Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2007-07","conditions":"Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury","enrollment":1},{"nctId":"NCT01064518","phase":"PHASE2","title":"Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2010-01","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":90},{"nctId":"NCT00884234","phase":"PHASE2","title":"Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2009-02","conditions":"Lateral Canthal Lines","enrollment":30},{"nctId":"NCT00234546","phase":"PHASE4","title":"Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity","status":"COMPLETED","sponsor":"Ipsen","startDate":"2003-02","conditions":"Muscle Spasticity, Cerebrovascular Accident","enrollment":162},{"nctId":"NCT01237977","phase":"PHASE3","title":"Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2009-11-23","conditions":"Skin Aging","enrollment":314},{"nctId":"NCT01271452","phase":"PHASE4","title":"Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09","conditions":"Glabellar Lines","enrollment":224},{"nctId":"NCT02479139","phase":"PHASE2","title":"Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06-03","conditions":"Hyperhidrosis","enrollment":145},{"nctId":"NCT01860196","phase":"PHASE4","title":"Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2013-06","conditions":"Adult Cerebral Palsy","enrollment":17},{"nctId":"NCT03193346","phase":"PHASE3","title":"BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2017-07-03","conditions":"Migraine Disorders","enrollment":""},{"nctId":"NCT03193359","phase":"PHASE3","title":"Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2018-01-15","conditions":"Migraine Disorders","enrollment":""},{"nctId":"NCT02147561","phase":"PHASE4","title":"A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Migraine Disorders","enrollment":280},{"nctId":"NCT01529788","phase":"PHASE4","title":"Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study","status":"COMPLETED","sponsor":"The Maas Clinic","startDate":"2009-09","conditions":"Intrinsic Aging of Skin, Solar Elastosis","enrollment":90},{"nctId":"NCT01124565","phase":"PHASE2","title":"Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2010-05","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":40},{"nctId":"NCT00968825","phase":"PHASE2","title":"Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2009-07","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":73},{"nctId":"NCT00968942","phase":"PHASE2","title":"Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2009-08","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":36},{"nctId":"NCT00770029","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-10","conditions":"Moderate to Severe Glabellar Frown Lines","enrollment":276},{"nctId":"NCT01391312","phase":"PHASE4","title":"Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-06","conditions":"Glabellar Frown Lines","enrollment":40},{"nctId":"NCT01098019","phase":"PHASE3","title":"Treatment of Notalgia Paresthetica With Xeomin","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2010-04","conditions":"Notalgia Paresthetica","enrollment":20},{"nctId":"NCT00541723","phase":"PHASE3","title":"Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2007-09","conditions":"Lateral Periorbital Wrinkles","enrollment":111},{"nctId":"NCT01297634","phase":"PHASE4","title":"Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle","status":"COMPLETED","sponsor":"Ivo Pitanguy Institute","startDate":"2011-05","conditions":"Wrinkles","enrollment":64},{"nctId":"NCT00770211","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-10","conditions":"Moderate to Severe Glabellar Frown Lines","enrollment":271},{"nctId":"NCT00752297","phase":"PHASE3","title":"Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows","status":"COMPLETED","sponsor":"Mentor Worldwide, LLC","startDate":"2007-06","conditions":"Glabellar Rhytides","enrollment":402},{"nctId":"NCT00752050","phase":"PHASE3","title":"Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows","status":"COMPLETED","sponsor":"Mentor Worldwide, LLC","startDate":"2007-11","conditions":"Glabellar Rhytides, Frown Lines Between the Eyebrows","enrollment":699},{"nctId":"NCT00430586","phase":"PHASE2","title":"Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2006-11","conditions":"Glabellar Frown Lines","enrollment":191},{"nctId":"NCT00959907","phase":"PHASE4","title":"Comparison of Two Commercial Preparations of Botulinum Toxin Type A","status":"COMPLETED","sponsor":"Hexsel Dermatology Clinic","startDate":"2005-05","conditions":"Wrinkles in Frontal Area","enrollment":29},{"nctId":"NCT00651690","phase":"PHASE2","title":"Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment","status":"COMPLETED","sponsor":"Allergan","startDate":"2004-03","conditions":"Stroke, Muscle Spasticity","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Botulinum Toxin Type-A (day 0)","genericName":"Botulinum Toxin Type-A (day 0)","companyName":"Ivo Pitanguy Institute","companyId":"ivo-pitanguy-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Botulinum toxin type-A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Facial wrinkles and expression lines (aesthetic use), Blepharospasm, Cervical dystonia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}